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by-nc-nd/4.0/).See Clinical Research on Page 1235P atent protection for pharma-ceuticals in the United States is
very robust and perhaps there is no
greater example than epoetin alfa.
Since the approval of epoetin alfa
by the Food and Drug Administra-
tion (FDA) in 1989, the developer,
Amgen (Thousand Oaks, CA), has
successfully defended its patent
against competing agents, such as
epoetin beta (Chugai-Upjohn,
Rosemont, IL), epoetin delta (Shire,
Lexington, MA), and methoxy
polyethylene glycol-epoetin beta
(CERA; Roche, Basel, Switzerland).
The US patent on epoetin alfa
expired in 2015, opening the way
for competition by products other
than Amgen’s own darbepoetin.
The ﬁrst non-Amgen erythropoi-
esis-stimulating agent (ESA) to
enter the US market was CERA,
which had previously been
approved by the FDA as a new
drug under a biologic licenseCorrespondence: Jay B. Wish, Depart-
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through the 351(a) pathway must
undergo expensive clinical testing,
the cost of which is ultimately
passed on to the consumer. ESAs
are biologic drugs, deﬁned by the
FDA as “a virus, therapeutic serum,
toxin, antitoxin, blood, blood
component or derivative, allergenic
product, protein (except any chem-
ically synthesized polypeptide), or
analogous product . . . applicable
to the prevention, treatment of
cure of a disease or condition of hu-
man beings.”
Because they are more structur-
ally complex than small-molecule
drugs, biologics are considerably
more expensive to develop and
produce; those costs also are
passed on to the consumer, which
limits patient access to important
therapeutic agents. A biosimilar
agent is deﬁned by the FDA as “a
biologic that is highly similar to
the reference or originator prod-
uct, with no clinically meaningful
differences in terms of the safety,
purity, and potency regardless of
minor differences in clinically
inactive components.” Biosimilar
agents also are expensive to1199produce, but some of their cost can
be decreased by an expedited
regulatory approval process in the
United States: the biologic license
application for biosimilar agents,
351(k) enacted in 2009, which de-
creases the time and cost burden of
the extensive clinical testing
required under the 351(a)
pathway. The 351(k) pathway is
based on the “comparability prin-
ciple”: if A leads to C, and B is
comparable to A, then B leads to C.
The burden on the developer of a
biosimilar agent is to demonstrate
structural, functional, pharmaco-
kinetic, and pharmacodynamic
high similarity with the reference
biologic. If this is achieved, the
351(k) pathway allows for a
signiﬁcantly lower burden of
clinical trial data than that was
required for the reference biologic
under the 315(a) pathway.1 The
enactment of the 351(k) pathway
in the United States was driven by
very favorable results of a similar
pathway to expedite the approval
process of lower-cost biosimilar
agents in the European Union (EU)
where patent protection is not as
robust as in the United States. The
ﬁrst biosimilar ESAs were
approved in the EU in 2007; it has
been estimated that the use of
these agents has led to 15% to
30% cost savings versus originator
ESAs.2
The primary safety concern
with ESAs in general, and bio-
similar ESAs in particular, is pure
red cell aplasia (PRCA), which re-
sults from the development of an-
tibodies against the ESA that cross
react with native erythropoietin,
leading to the loss of red blood cell
precursors in the bone marrow and
severe anemia. PRCA has been a
signiﬁcant issue in countries with
poor regulation of pharmaceuticals
where biosimilar-like (not truly
biosimilar by the strict deﬁnition
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market without adequate safe-
guards regarding manufacturing,
packaging, and distribution. Pra-
ditpornsilpa et al.3 noted an
alarming increase in the prevalence
of PRCA in Thailand to 1 in 2068
patients at risk, concomitant with
the higher penetration of poorly
regulated biosimilar-like epoetins
into the market. Such reports have
undeservedly tarnished the excel-
lent safety record of true biosimilar
ESAs. Nonetheless, clusters of
PRCA have been associated with
originator ESAs and biosimilar
ESAs, usually attributable to
packaging issues and not to the
inferiority of the ESA molecule.
Eprex, an originator epoetin alfa
product sold in Europe, was asso-
ciated with a PRCA cluster that
was attributed to the interaction
between polysorbate-80 (a stabi-
lizer that replaced human albumin
because of concerns regarding
prion transmission by a human
protein) and the rubber in the
gasket of preﬁlled syringes. Once
the problem was identiﬁed and the
gasket was coated with latex, the
cluster of PRCA was arrested.4
Two cases of PRCA occurred with
a biosimilar version of epoetin alfa
approved in the EU, Binocrit,
which interacted with tungsten
used to manufacture preﬁlled sy-
ringes.5 Virtually all cases of PRCA
occur with subcutaneous (s.c.)
administration of the ESA.
Following their respective PRCA
clusters, s.c. administration of
Eprex was contraindicated from
2002 to 2006, and the EU withheld
approval for s.c. administration of
Binocrit from 2008 to 2016.
Therefore, it is vitally important
for all newly approved ESAs to
demonstrate their safety when
administered s.c., particularly
with regard to immunogenicity.
In this issue of KI Reports,
Fishbane et al.6 describe the results
of phase 3 testing of a biosimilar1200epoetin alfa administered s.c. in
hemodialysis patients as part of the
US FDA approval process through
the 351(k) pathway. This bio-
similar epoetin alfa has been
designated epoetin alfa-epbx by
the nomenclature system recently
announced by the FDA to distin-
guish multiple biosimilars from
each other and from the reference
product to promote pharmacovigi-
lance. The agent was known as
epoetin-hospira during the FDA
approval process and has taken the
brand name Retacrit in the United
States, which is the same as its
brand name in the EU, where it
was approved in 2007 for both i.v.
and s.c. administration. It was
approved by the FDA on May 15,
2018, for i.v. and s.c. administra-
tion. The results of phase 3 testing
of i.v.-administered epoetin alfa-
epbx versus originator epoetin
alfa in hemodialysis patients have
previously been published7 and
reveal no signiﬁcant efﬁcacy or
safety differences between the 2
products. In the i.v. study of 612
patients, 5 tested positive for anti-
recombinant human erythropoietin
antibodies at baseline, and 2 addi-
tional patients (1 per study arm)
developed anti-recombinant hu-
man erythropoietin antibodies
while on study treatment. All pa-
tients tested negative for neutral-
izing antibodies, and no patient in
either group experienced an event
of PRCA. The s.c. study was
required by the FDA because, as
noted previously, the development
of neutralizing antibodies and
PRCA occurs almost exclusively in
patients treated with s.c. ESAs. In
the s.c. study,6 investigators ran-
domized 246 hemodialysis patients
who had previously been treated
with epoetin alfa (i.v. or s.c.) to s.c.
epoetin alfa-epbx or s.c. originator
epoetin alfa. They were followed
for 16 weeks on study drug; again,
efﬁcacy and safety were compara-
ble between the 2 study arms.KThree patients (1 treated with
epoetin alfa-epbx and 2 treated
with reference epoetin alfa) devel-
oped anti-recombinant human
erythropoietin antibodies while
receiving study drug; however, no
patient in either treatment arm
developed neutralizing antibodies,
PRCA, or hypersensitivity consis-
tent with immunogenic response to
epoetin.
Despite reassurance regarding
the lack of neutralizing antibody
or PRCA development with a
biosimilar ESA such as epoetin
alfa-epbx in a highly regulated
environment such as the United
States or EU, there may be ne-
phrologists who take a conserva-
tive approach to the adoption of
such agents pending postmarket-
ing experience with many more
patients over longer periods of
time. They cite the experience
with peginesatide, a PEGylated
peptide with erythropoietin re-
ceptor activity (not a biosimilar
protein) that was voluntarily
recalled following 49 cases of
anaphylaxis-like reactions,
including 7 fatalities. These re-
actions occurred exclusively with
the multidose vial formulation of
peginesatide, leading to suspicion
that an interaction between one of
the preservatives and the drug led
to its immunogenicity.8 Although
peginesatide was not a biosimilar,
there remains some confusion if
not distrust of the biosimilar cate-
gory of agents because they have
not undergone the same pre-
approval vetting by the FDA as
originator biologics. To address
these and other concerns regarding
the use of biosimilar agents in
nephrology, the National Kidney
Foundation held a workshop in
2015 to demystify this class of
agents and to provide context
regarding their adoption.9 The
workgroup acknowledged the
need for evidence-based education
of providers and patientsidney International Reports (2019) 4, 1199–1202
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Figure 1. Timeline of erythropoiesis-stimulating agents (ESAs) in the United States and European Union (EU). CERA, methoxy polyethylene
glycol-epoetin beta.
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ily lower cost to patients and the
health care system) and disadvan-
tages (unknown risks due to rela-
tive lack of clinical experience
with fewer patients over shorter
duration) of biosimilars versus
originator products; the need for
postmarketing pharmacovigilance
of at least 2 to 4 years (as is done in
the EU) to detect safety issues that
were not apparent in registration
studies; the need for postmarket-
ing studies with patient-reported
outcomes that inform choice of
therapeutic agent; and the need for
increased clarity from the FDA
regarding such issues as biosimilar
interchangeability, substitution,
and extrapolation. Epoetin alfa-
epbx does not have an inter-
changeability designation (a
designation the sponsor did not
seek), so the pharmacist or pre-
scription drug plan cannot substi-
tute the biosimilar for the
originator agent without informing
the prescriber. Nonetheless, many
prescription drug plans in the
United States now have a prior
approval process for ESAs that re-
quires the prescriber to use epoetin
alfa-epbx as ﬁrst-line therapy for
anemia in patients with non–dial-
ysis-dependent chronic kidney
disease. For patients on dialysis,
the choice of ESA is driven by theKidney International Reports (2019) 4, 1199–1202formulary of the dialysis provider.
In the United States, the 2 largest
dialysis providers have long-term
contracts for originator ESAs, so
that leaves only 20% of the dial-
ysis market open to penetration by
a biosimilar product. Of note is a
recent observational study from
Japan that suggests the use of
shorter-acting ESAs (epoetin alfa,
epoetin beta, and a biosimilar of
epoetin alfa) was associated lower
death rates from all causes, car-
diovascular disease, cardiac dis-
ease, stroke, non-cardiovascular
disease, stroke, and malignancy,
than longer-acting ESAs (darbe-
poetin and CERA).10 The reason for
this difference in outcomes is un-
clear, but a perception that
shorter-acting ESAs are safer could
accelerate the adoption of the
shorter-acting epoetin alfa-epbx
over longer-acting alternatives
that are also more expensive. The
timeline of ESAs currently avail-
able in the United States and EU is
shown in Figure 1.
The future of all originator and
biosimilar ESA therapy is unclear
following the potential approval of
the hypoxia-inducible factor sta-
bilizer class of drugs, which are
orally administered and often
effective in patients who are ESA
resistant. The oral route of
hypoxia-inducible factor stabilizeradministration may have the
greatest appeal among non-
hemodialysis patients, especially
those who would otherwise be
injecting shorter-acting ESAs, such
as epoetin and its biosimilars.
However, the value proposition of
the hypoxia-inducible factor sta-
bilizers has yet to be clariﬁed, as
pricing and long-term safety are
not established. The safety of
s.c.-administered epoetin alfa-epbx
reported in this issue of KI Reports
provides reassurance to pre-
scribers, payers, and patients that
this new less expensive option in
the United States for the treatment
of anemia of chronic kidney dis-
ease has a place in the current ESA-
based paradigm.DISCLOSURE
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